BRISTOL MYERS SQUIBB

Bristol Myers Squibb and Johnson & Johnson discontinued the Phase 3 Librexia ACS trial of milvexian after an interim analysis showed the drug was unlikely to meet its primary efficacy endpoint.

Pfizer sold 54.7% of its stake in German partner BioNTech, retaining approximately 1.66 million shares valued at $163.5 million as of September 30.

Ataciguat, an oral soluble guanylate cyclase activator, demonstrated significant improvements in cardiac function and slowed aortic valve calcium progression in a Phase 2 trial of 23 patients with moderate calcific aortic valve stenosis.

DBV Technologies has appointed Kevin Trapp as Chief Commercial Officer to lead global commercial strategy for the Viaskin Peanut patch ahead of anticipated regulatory submissions.

The Health Resources and Services Administration has approved eight pharmaceutical companies to participate in the 340B Rebate Model Pilot Program, which will begin on January 1, 2025.

The U.S. FDA released draft guidance proposing to reduce human clinical study requirements for certain biosimilar drugs and treat them more like generic medications to accelerate market availability.

Experimental CAR-T therapies from Cabaletta Bio and Bristol Myers Squibb have induced complete remissions in patients with severe inflammatory muscle disease, according to dual clinical trial results presented this week.

Evotec received a $25 million payment from Bristol Myers Squibb for achieving scientific progress in their strategic neuroscience partnership focused on neurodegenerative diseases.

Bristol Myers Squibb presented Phase 1 data from 71 patients showing its CD19 NEX-T CAR-T therapy achieved immune reset across three severe autoimmune diseases with 94% of patients remaining off immunosuppressive therapy.

Biokin secured a $250 million milestone payment from Bristol Myers Squibb in October 2025, marking the largest antibody-drug conjugate milestone payment among Chinese innovative drug out-licensing deals.